Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to the planned development program for amrubicin, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, the potential failure of amrubicin, to demonstrate safety and efficacy in the Phase 3 study discussed in this release or in other clinical and non-clinical testing; the ability to complete regulatory submissions and gain regulatory approvals in a timely manner; the ability to initiate and complete trials at the referenced times; the impact of competition from other products under development by Pharmion's competitors; the uncertainty of the regulatory environment and changes in the health policies of various countries; acceptance and demand for new pharmaceutical products and new therapies; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; failure of third-party manufacturers to produce the product volumes required on a timely basis and fluctuations in currency exchange rates. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no o
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" ... appointments: Todd Martensen has ... created role of Chief Commercial Officer, to oversee KLOX,s ... photoconverter gel for the treatment of chronic and other ... recently approved in Europe . Mr. ...
(Date:11/21/2014)... Michael DeMarco (42) erinnert sich ... Februar 2014 zugetragen hat. Seine Tochter Aly Demarco (13) ... Video - http://youtu.be/5cVoMCe0uiE „Man ... Training zu machen", erzählt Michael DeMarco . „Meine ... begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf dem Fahrrad, ...
(Date:11/21/2014)... 2014   Coqui RadioPharmaceuticals Corp. , a medical ... producer of Molybdenum-99 (Mo-99), is proud to announce it ... to design its Medical Isotope Production Facility (MIPF) in ... parent isotope of Technetium-99, which is used in 80 ... passed legislation making it a national priority to produce ...
Breaking Medicine Technology:KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... 2011  Quest Diagnostics Incorporated (NYSE: DGX ), ... services, today announced that its Board of Directors has ... effective immediately. Including Mr. Ring, the Board has nine ... of C. R. Bard, Inc., a leading multinational developer, ...
... Dec. 7, 2011 Aoxing Pharmaceutical (NYSE Amex: ... pharmaceutical company focusing on research, development, manufacturing and ... today announced that its operating subsidiary in China, ... three-way financing agreement with Shijiazhuang Construction Investment Group ...
Cached Medicine Technology:Quest Diagnostics Adds Timothy M. Ring to Board of Directors 2Aoxing Pharmaceutical Company Announces $3.2 Million Financing 2Aoxing Pharmaceutical Company Announces $3.2 Million Financing 3
(Date:11/22/2014)... A petition seeking a ban on ... in minimally-invasive hysterectomies and fibroid removal surgeries has gained ... October, Bernstein Liebhard LLP reports. According to Change.org, ... 21st, 2014. That represents an increase of 456 signatures ... to the campaign.* , The campaign to ban uterine ...
(Date:11/22/2014)... November 22, 2014 This month has been ... because it has received many positive reviews from some renowned ... of its products by launching a new selection of wonderful ... global customers can enjoy free shipping and up to an ... Stylish ladies can always find the most suitable dress at ...
(Date:11/22/2014)... Sandbridge Capital, a private equity ... consumer brand sector, acquired a minority stake in ... to help fund BackJoy’s global growth and accelerate ... proprietary apparel and footwear lines. Sandbridge Capital Managing ... Directors. , BackJoy is a high-growth health and ...
(Date:11/22/2014)... November 22, 2014 A Xarelto lawsuit has ... who is seeking $10 million in damages from the makers ... According to the lawsuit, the woman began using Xarelto in ... alleges in her lawsuit she suffered life-threatening bleeding in July ... injuries, pain, suffering and emotional distress. The lawsuit purports that ...
(Date:11/22/2014)... Nov. 21, 2014 (HealthDay News) -- The widely used ... death and hospitalization among patients who have the heart ... failure, a new study finds. Atrial fibrillation is ... linked to a rise in risk for stroke among ... a century to help treat irregular heartbeat, the authors ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3
... -- The use of long-distance video and data hookups to ... provides the same level of care as having everyone in ... at the Canadian Stroke Congress. The study found that ... Telestroke received an important stroke drug, tPA, at the same ...
... Gordon HealthDay Reporter , MONDAY, Oct. 3 (HealthDay ... sexually transmitted human papillomavirus (HPV) rose dramatically over two decades, ... these types of tumors might become the leading form of ... 1984 and 1989, just 16.3 percent of oral cancer samples ...
... , MONDAY, Oct. 3 (HealthDay News) -- In Utah, ... rate similar to those suspected of adult homicide, and they ... abuse homicide offenders are those who have failed to care ... ranks as one of the top five causes of childhood ...
... Sinai School of Medicine have found that $6.7 billion was ... medications in primary care, with 86 percent of that cost ... cholesterol. The findings are published in a research letter in ... Internal Medicine , one of the JAMA/Archives journals. ...
... cancer patients are given the choice, they are significantly more ... quality of life six months after treatment, compared to a ... scientific session, October 5, 2011, at the 53rd Annual Meeting ... finding challenges the perception that older cancer patients do not ...
... TORONTO, Ont., Oct. 3, 2011Studies that examined the possible link ... it,s impossible to reach a firm conclusion about the controversial ... found the blockages known as chronic cerebrospinal venous insufficiency, or ... than those who do not. But a team of ...
Cached Medicine News:Health News:Telestroke the next best thing 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 3Health News:Conviction Rates Similar for Suspects of Child, Adult Murder in Utah 2Health News:New research shows $6.7 billion spent on unnecessary tests and treatments in one year 2Health News:Cancer patients in their 60s are tech-savvy 2Health News:Researchers review studies on CCSVI-MS link 2
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 4.0mm....
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: